Larry G Stambaugh serves as Molecular Assemblies’ Chairman of the Board. He is the founding principal at Apercu Partners, where he serves as an advisor to private, public and non-profit management and boards. Continue reading
Michael J. Kamdar joined Molecular Assemblies in 2016 as President, CEO and Board Member. An industry veteran with an expertise in business development and financing, Mr. Kamdar has accounted for deal transactions in excess of $1 billion and has raised more than $400 million from venture capital and the public capital markets.
Bill Efcavitch co-founded Molecular Assemblies in 2013 and serves as Chief Scientific Officer. He was a founding member of Applied Biosystems, as the company’s ninth employee. Continue reading
Dr. Bastian has more than 27 years of international leadership experience in leading life science and healthcare corporations that deliver innovative products, custom products, and services in research-use-only and regulated markets. Continue reading
Mr. Hwang currently is Senior Director of Strategy and Corporate Development at Agilent Technologies and a Managing Director of Agilent’s Early Stage Partnership Program that helps early stage companies navigate the complex life science ecosystem. He has more than 18 years of experience in corporate development, venture investment, corporate financing, and M&A.
As President & CEO of Codexis since June 2012, John has been at the helm of the company through its turnaround and subsequent growth, positioning Codexis as a leader bringing protein-based innovations into a growing list of partnerships and industries.
Dr. Todd Peterson is Founder and Principal at GenApex Biotechnology Consulting, a board practice, investment, and advisory services LLC based in Coronado, California. He has more than 35 years of experience in biotechnology and life sciences research and development across the areas of molecular and cell biology, nucleic acids, and genomics product and technology development.
Hallie Kuhn, Ph.D. is Vice President, Science & Technology, at Alexandria Real Estate Equities, Inc. and its corporate venture arm, Alexandria Venture Investments. Continue reading